Claims:

A pharmaceutical preparation which provides a dosage form of Tamoxifen, characterised in that the dosage form is that of a solution in a suitable solvent of at least 1.5 g/ml of Tamoxifen Citrate.

Subj

5

- A pharmaceutical preparation according to claim 1, characterised in that the solvent comprises the following components: (a) of from 10% to 20% by weight of ethanol;
  (b) of from 10% to 60% by weight of a glycol; and (c) water, optionally containing additives, in a volume percentage adding up to 100% by volume.
- 3. A pharmaceutical preparation according to claim 2, characterised in that the glycol component is a mixture of propylene glycol and glycerol.
- 4. A pharmaceutical preparation according to claim 3, characterised in that the water component (c) contains a bulk-sweetening agent.
  - 5. A pharmaceutical preparation according to claim 4, characterised in that the bulk-sweetening agent is of from 15% to 25 % by weight of sorbitol.

20

6. A pharmaceutical preparation according to claim 5, characterised in that the solvent comprises the following components: 15% by weight of ethanol, 10% by weight of propylene glycol, 50% by weight of glycerol, 20% by weight of a solution of 70% by weight of sorbitol in water, and water in a volume percentage adding up to 100% by volume.

25 July 7.

A process for the preparation of a solution according to claim 2, comprising the steps of dissolving the Tamoxifen Citrate in the mixed ethanol and glycol components and then adding the other components.

8. A process for the preparation of a solution according to claim 2, comprising the steps of first dispersing Tamoxifen Citrate in the glycol component and then adding the ethanol component and the water component.

5

9. A process according to claim 7, characterised in that a solution in accordance with claim 3 is made by first dispersing Tamoxifen Citrate in the propylene glycol to form a dispersion, adding dispersion to the glycerol and, then adding the ethanol component to form a solution.



